BBOT Bridgebio Oncology Therapeutics, Inc.
Fundamentals / CIK 0001869105 / USDBridgebio Oncology Therapeutics, Inc. reported $346.2M in total assets and a net loss of $171.5M through December 31, 2025 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open BBOT in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025-- Dec 31, 2025
-
Operating Income FY 2025-$187.3M Operating profit
-
Net Income FY 2025-$171.5M GAAP bottom line
-
Diluted EPS FY 2025-$2.14 Split-adjusted
-
Free Cash Flow FY 2025-$151.0M Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$193.9M Total debt: $2.38M
Annual revenue and net income
3 fiscal years (2023 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Research & Development | $121.2M | $73.11M | -- |
| Total Operating Expenses | $145.8M | $80.86M | -- |
| Operating Income | -$145.8M | -$80.86M | -$42K |
| EBITDA | -$145.5M | -$80.66M | -- |
| Interest Income | $11.34M | $8.45M | -- |
| Income Tax Expense | $0 | $0 | -- |
| Net Income | -$134.0M | -$74.28M | -$42K |
| Basic EPS | -$4.30 | -$5,756.41 | -- |
| Diluted EPS | -$4.30 | -$5,756.41 | -- |
| Basic Shares Outstanding | 31.1M | 12.9K | -- |
| Diluted Shares Outstanding | 31.1M | 12.9K | -- |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Research & Development | $29.59M | $49.23M | $39.80M | $38.07M | $35.05M | $27.44M | $20.64M | -- |
| Total Operating Expenses | $37.49M | $60.19M | $46.18M | $43.41M | $49.18M | $30.09M | $23.14M | -- |
| Operating Income | -$37.49M | -$60.19M | -$46.18M | -$43.41M | -$49.18M | -$30.09M | -$23.14M | -$21.88M |
| EBITDA | -$37.39M | -$60.09M | -$46.10M | -$43.32M | -$49.08M | -$29.99M | -$23.08M | -- |
| Interest Income | $3.26M | $3.55M | $3.94M | $4.42M | $3.44M | $2.07M | $1.99M | $2.25M |
| Income Tax Expense | $0 | $0 | -- | $0 | $0 | $0 | $0 | -- |
| Net Income | -$34.18M | -$56.45M | -$42.11M | -$38.80M | -$44.76M | -$28.43M | -$22.05M | -$19.69M |
| Basic EPS | -$0.43 | -$705.20 | -$526.11 | -- | -$1.03 | -$566.46 | -$54.23 | -- |
| Diluted EPS | -$0.43 | -$705.20 | -$526.11 | -- | -$1.03 | -$566.46 | -$54.23 | -- |
| Basic Shares Outstanding | 80.2M | 80.1M | 80.0K | -- | 43.5M | 50.2M | 406.7K | -- |
| Diluted Shares Outstanding | 80.2M | 80.1M | 80.0K | -- | 43.5M | 50.2M | 406.7K | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & Cash Equivalents | $373.7M | $30.85M | $0 |
| Short-Term Investments | $51.77M | $124.8M | -- |
| Cash & Short-Term Investments | $425.5M | $155.6M | $0 |
| Total Current Assets | $432.4M | $158.7M | -- |
| Property, Plant & Equipment, Net | $956K | $490K | -- |
| Long-Term Investments | $0 | -- | -- |
| Other Non-Current Assets | $12.57M | $4.99M | -- |
| Total Non-Current Assets | $15.98M | $5.61M | -- |
| Total Assets | $448.4M | $164.3M | $333K |
| Accounts Payable | $1.37M | $3.07M | -- |
| Total Current Liabilities | $35.04M | $19.58M | $396K |
| Total Non-Current Liabilities | $2.24M | $0 | $0 |
| Total Liabilities | $37.28M | $19.58M | $396K |
| Total Debt (incl. Leases) | $2.77M | -- | -- |
| Common Stock | $8.0K | $0 | -- |
| Retained Earnings | -$356.6M | -$222.5M | -$89K |
| Accumulated Other Comp. Income | $16K | $348K | -- |
| Total Stockholders' Equity | $411.1M | -$178.6M | -$115.6M |
| Total Equity | $411.1M | -$178.6M | -$115.6M |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $76.48M | $54.06M | $52.66M | $373.7M | $408.7M | $664K | $963K | $30.85M |
| Short-Term Investments | $117.4M | $171.6M | $199.6M | $51.77M | $59.54M | -- | -- | $124.8M |
| Cash & Short-Term Investments | $315.3M | $344.1M | $388.9M | $425.5M | $468.3M | $664K | $963K | $155.6M |
| Total Current Assets | $208.3M | $242.4M | $266.5M | $432.4M | $476.0M | $877K | $1.24M | $158.7M |
| Property, Plant & Equipment, Net | $815K | $878K | $938K | $956K | $827K | -- | -- | $490K |
| Long-Term Investments | $121.5M | $118.4M | $136.6M | $0 | -- | -- | -- | -- |
| Other Non-Current Assets | $13.50M | $12.79M | $11.24M | $12.57M | $5.38M | -- | -- | $4.99M |
| Total Non-Current Assets | $137.9M | $134.3M | $151.1M | $15.98M | $8.78M | $196.5M | $194.4M | $5.61M |
| Total Assets | $346.2M | $376.7M | $417.6M | $448.4M | $484.8M | $197.4M | $195.7M | $164.3M |
| Accounts Payable | $10.26M | $6.73M | $12.09M | $1.37M | $3.65M | -- | -- | $3.07M |
| Total Current Liabilities | $51.03M | $51.63M | $43.26M | $35.04M | $35.71M | $2.63M | $1.87M | $19.58M |
| Total Non-Current Liabilities | $1.81M | $1.96M | $2.11M | $2.24M | $2.38M | $5.52M | $5.52M | $0 |
| Total Liabilities | $52.84M | $53.59M | $45.37M | $37.28M | $38.09M | $8.15M | $7.39M | $19.58M |
| Total Debt (incl. Leases) | $2.38M | $2.51M | $2.64M | $2.77M | $2.89M | -- | -- | -- |
| Common Stock | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | -- | -- | $0 |
| Retained Earnings | -$489.3M | -$455.1M | -$398.7M | -$356.6M | -$317.8M | -$7.27M | -$6.15M | -$222.5M |
| Accumulated Other Comp. Income | -$1.70M | -$959K | -$981K | $16K | $36K | -- | -- | $348K |
| Total Stockholders' Equity | $293.4M | $323.1M | $372.3M | $411.1M | $446.7M | -$227.7M | -$200.0M | -$178.6M |
| Total Equity | $293.4M | $323.1M | $372.3M | $411.1M | $446.7M | -$227.7M | -$200.0M | -$178.6M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Net Income | -$134.0M | -$74.28M | -$42K |
| Depreciation & Amortization | $280K | $208K | -- |
| Stock-Based Compensation | $5.87M | $4.42M | -- |
| Change in Payables | -$1.84M | $2.50M | -- |
| Operating Cash Flow | -$113.9M | -$55.03M | -- |
| Capital Expenditure | -$606K | -$49K | -- |
| Free Cash Flow | -$114.5M | -$55.08M | -- |
| Purchases of Investments | -$83.92M | -$154.4M | -- |
| Investing Cash Flow | $73.33M | -$120.5M | -- |
| Common Stock Issued | $112.3M | -- | -- |
| Financing Cash Flow | $383.4M | $206.3M | -- |
| Net Change in Cash | $342.8M | $30.73M | -- |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$34.18M | -$56.45M | -$42.11M | -$38.80M | -$44.76M | -$28.43M | -$22.05M | -$19.69M |
| Depreciation & Amortization | $100K | $100K | $74K | $84K | $100K | $100K | $54K | -- |
| Stock-Based Compensation | $4.75M | $7.23M | $3.87M | $2.95M | $1.43M | $36K | $627K | $587K |
| Change in Payables | $3.53M | -$5.33M | $10.69M | -$2.42M | $2.09M | -$2.05M | $537K | -- |
| Operating Cash Flow | -$28.36M | -$44.36M | -$35.92M | -$42.23M | -$28.77M | -$23.29M | -$19.60M | -$15.04M |
| Capital Expenditure | -$13K | -$47K | -$24K | -$73K | -$140K | -$231K | -$162K | -- |
| Free Cash Flow | -$28.38M | -$44.41M | -$35.94M | -$42.31M | -$28.91M | -$23.52M | -$19.76M | -- |
| Purchases of Investments | -$16.95M | -$7.54M | -$311.6M | -$21.04M | -$4.46M | -$33.98M | -$24.43M | -- |
| Investing Cash Flow | $50.34M | $45.73M | -$285.4M | $7.77M | $40.55M | $9.64M | $15.37M | $25.56M |
| Common Stock Issued | $0 | $0 | $112.3M | -- | -- | -- | -- | -- |
| Financing Cash Flow | $442K | $37K | $295K | -$586K | $365.4M | $18.96M | -$404K | $52K |
| Net Change in Cash | $22.42M | $1.41M | -$321.0M | -$35.05M | $377.2M | $5.30M | -$4.63M | $10.57M |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Return on Equity (ROE) | -32.6% | -- | -- |
| Return on Assets (ROA) | -29.9% | -45.2% | -12.5% |
| Current Ratio | 12.34x | 8.10x | -- |
| Quick Ratio | 12.14x | 7.95x | 0.00x |
| Debt to Equity | 0.01x | -- | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -58.5% | -56.4% | -41.4% | -32.6% | -25.7% | -- | -- | -- |
| Return on Assets (ROA) | -49.5% | -48.3% | -36.9% | -29.9% | -23.7% | -44.3% | -41.3% | -45.2% |
| Current Ratio | 4.08x | 4.69x | 6.16x | 12.34x | 13.33x | 0.33x | 0.66x | 8.10x |
| Quick Ratio | 6.18x | 6.66x | 8.99x | 12.14x | 13.11x | 0.25x | 0.51x | 7.95x |
| Debt to Equity | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | -- | -- | -- |